Institut de Bioenginyeria de Catalunya (IBEC), Barcelona 08028, Spain.
Institute of Chemical Research of Catalonia (ICIQ), The Barcelona Institute of Science and Technology, Tarragona 43007, Spain.
Nat Commun. 2016 Jul 20;7:12221. doi: 10.1038/ncomms12221.
Light-regulated drugs allow remotely photoswitching biological activity and enable plausible therapies based on small molecules. However, only freely diffusible photochromic ligands have been shown to work directly in endogenous receptors and methods for covalent attachment depend on genetic manipulation. Here we introduce a chemical strategy to covalently conjugate and photoswitch the activity of endogenous proteins and demonstrate its application to the kainate receptor channel GluK1. The approach is based on photoswitchable ligands containing a short-lived, highly reactive anchoring group that is targeted at the protein of interest by ligand affinity. These targeted covalent photoswitches (TCPs) constitute a new class of light-regulated drugs and act as prosthetic molecules that photocontrol the activity of GluK1-expressing neurons, and restore photoresponses in degenerated retina. The modularity of TCPs enables the application to different ligands and opens the way to new therapeutic opportunities.
光控药物允许远程光切换生物活性,并基于小分子实现合理的治疗方法。然而,只有可自由扩散的光致变色配体被证明可以直接在内源性受体中发挥作用,而共价连接的方法则依赖于遗传操作。在这里,我们引入了一种化学策略,用于共价连接和光切换内源性蛋白质的活性,并证明了其在 kainate 受体通道 GluK1 中的应用。该方法基于含有短寿命、高反应性锚固基团的光致变色配体,该锚固基团通过配体亲和力靶向感兴趣的蛋白质。这些靶向共价光开关 (TCP) 构成了一类新的光控药物,作为假体分子,可光控表达 GluK1 的神经元的活性,并恢复退化视网膜的光反应。TCP 的模块化使其能够应用于不同的配体,并为新的治疗机会开辟了道路。